Allard et al. showed that the combination of a CD73 inhibitor with anti-PD1 can increase survival in mice by increasing CD8+ T-cells, since CD73-positive tumor cells are usually resistant to ICI [236]. The gene discussed is PDCD1; the disease is neoplasm.